Table 2.
Anticoagulant activities of FG-derived oligosaccharides and their effects of on coagulation factors and cofactors
| Molecular mass | APTTa | Anti-FXase (IC50)b | Anti-FIIa/AT (IC50)b | Anti-FXa/AT (IC50)b | |
|---|---|---|---|---|---|
| Da | μg/ml | ng/ml | ng/ml | ng/ml | |
| FG | 70,130c | 4.13 ± 0.05 | 14.83 ± 0.49 | 530.8 ± 23.08 | 3341 ± 142 |
| dFG | 4005c | 12.03 ± 0.04 | 31.99 ± 2.33 | >100,000 | >100,000 |
| 3 | 2459 (dp8) | 47.40 ± 0.20 | 597.1 ± 60.10 | >100,000 | >100,000 |
| 2 | 1504 (dp5) | 334.3 ± 7.5 | >10,000 | >100,000 | >100,000 |
| 1 | 956 (dp3) | >1000 | >100,000 | >100,000 | >100,000 |
| R1d | 2459 (dp8) | 25.09 ± 0.31 | 239.7 ± 24.55 | >100,000 | >100,000 |
| R2d | 2805 (dp9) | 27.58 ± 0.89 | 219.4 ± 22.36 | >100,000 | >100,000 |
| LMWHe | 4500–5500 | 10.21 ± 0.09 | 70.94 ± 6.68 | 38.00 ± 0.96 | 75.57 ± 2.80 |
a Concentration required to double the APTT of human plasma.
b The IC50 value is the concentration of each agent required to inhibit 50% of protease activity.
c The molecular mass was determined by multiangle laser light scattering.
e LMWH, a low-molecular-weight heparin (enoxaparin), was used as a positive control from Sanofi–Aventis.